NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Kite Pharma, Inc. (NASDAQ: KITE) concerning possible violations of federal securities laws.
On May 8, 2017, Kite revealed that a cancer patient had died in April 2017 from brain swelling following treatment with its CAR-T therapy KTE-C19. Following this news, Kite stock has dropped as much as $11.54, or 14.11%, during intraday trading on May 8, 2017. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.